New randomized controlled trial demonstrates the efficacy of daxor's bva guided-care in heart failure patients

Data from study funded by nih presented at the american heart association annual meeting oak ridge, tn, nov. 13, 2023 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, today announces the presentation of data from a phase i national institute of health (nih) sponsored randomized control trial (rct) from two veterans affairs medical centers (boston , minneapolis), validating treatment decisions guided by the company's bva-100® diagnostic blood test benefitted patients with acute decompensated heart failure (adhf). data were presented at the american heart association scientific sessions 2023 at the pennsylvania convention center in philadelphia, pa on november 11, 2023.
DXR Ratings Summary
DXR Quant Ranking